ТУН Пин (US),ЧЖОУ Дэлян (US),ЧЖАН Джефф Дж. З. (US),ХИМСТРА Кэтрин (US),ФИШЕР Кристина М. (US),КЭТРОН Натаниэль (US),ШМИТТ Эрик А. (US),САНЗГИРИ Ешвонт Д. (US)
申请号：
RU2012131408/15
公开号：
RU2012131408A
申请日:
2010.12.21
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A pharmaceutical capsule comprising a capsule shell enclosing within themselves encapsulated in an amount of not more than about 1000 mg per capsule, liquid solution ABT-263 or a pharmaceutically acceptable salt thereof at a concentration equivalent of the free base of ABT-263, at least about 40 mg / ml in substantially neetanolnom carrier, which comprises as pharmaceutically acceptable excipients: (a) at least one phospholipid, (b) at least one solubilizing agent, at least one phospholipid, selected th from the group consisting of glycols, glycolides, glycerides and mixtures thereof, (c) at least one surfactant is non-phospholipid nature, and (d) at least one sulfur-containing antioxidant in an amount effective to reduce the AVT oxidative degradation -263 at hranenii.2. Capsule according to claim 1, wherein the ABT-263 present in the form of free osnovaniya.3. Capsule according to claim 2, in which said excipients are selected and included in amounts effective for maintaining in solution at least about 40 mg of the free base of ABT-263 in kapsulu.4. Capsule according to claim 1, wherein the amount of the above encapsulated liquid solution ranges from about 300 to about 600 mg per kapsulu.5. Capsule according to claim 1, wherein the at least one phospholipid comprises fosfatililholin.6. Capsule according to claim 1, wherein at least one solubilizing agent comprises one or more medium-triglitseridov.7. Capsule according to claim 6, wherein at least one solubilizing agent further comprises one or more medium-mono- and / or diglitseridov.8. Capsule according to claim 1, to1. Фармацевтическая капсула, содержащая капсульную оболочку, заключающую внутри себя инкапсулированный, в количестве не больше чем около 1000 мг на капсулу, жидкий раствор АВТ-263 или его фармацевтически приемлемой соли при концентрации эквивалента свободного основания АВТ-263, по крайней мере, около 40 мг/мл в, по существу, неэтанольном носителе, который включает в качестве фармацевтически приемле
